Your browser doesn't support javascript.
Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
Taylor, Sean C; Hurst, Beth; Martiszus, Ian; Hausman, Marvin S; Sarwat, Samar; Schapiro, Jeffrey M; Rowell, Sarah; Lituev, Alexander.
  • Taylor SC; GENSCRIPT USA INC., 860 Centennial Ave., Piscataway, NJ 08854, USA. Electronic address: sean.taylor@genscript.com.
  • Hurst B; Cayman Chemical, 1180 E. Ellsworth Road, Ann Arbor, MI 48108, USA.
  • Martiszus I; Cure-Hub, 12655 SW Beaverdam Rd., Beaverton, OR 97005, USA.
  • Hausman MS; FourthWall Testing LLC, 455 9th Street Suite 128, Winter Garden, FL 34787, USA.
  • Sarwat S; DYNEX Technologies, 14340 Sullyfield Circle, Chantilly, VA 20151-1621, USA.
  • Schapiro JM; Kaiser Permanente, 1795 A Second Street, Berkeley, CA 94710, USA.
  • Rowell S; Kaiser Permanente, 1795 A Second Street, Berkeley, CA 94710, USA.
  • Lituev A; Kaiser Permanente, 1795 A Second Street, Berkeley, CA 94710, USA.
Vaccine ; 39(39): 5688-5698, 2021 09 15.
Article in English | MEDLINE | ID: covidwho-1347852
ABSTRACT
The question associated with efficacy and longevity of SARS-CoV-2 protection post-vaccination is paramount. The cPass surrogate virus neutralization test (sVNT) has gained popularity globally as a dual application assay for 1. Accurate SARS-CoV-2 population surveillance (seroprevalence) analysis and 2. Revealing the presence of antibodies that block and effectively neutralize the interaction between the SARS-CoV-2 receptor binding domain and the host cell ACE2 receptor in recovered or vaccinated individuals. This study describes an approach for accurate quantification of neutralizing antibodies using the cPass sVNT with an automated workflow on the Tecan EVO and Dynex Agility platforms that is applicable to other liquid handling systems. This methodology was used to assess the stability of SARS-CoV-2 neutralizing antibodies between freeze/thaw and refrigerated sample storage conditions. Furthermore, a subset of twenty-five samples from SARS-CoV-2 infected/recovered individuals revealed a 600-fold difference in the neutralizing antibody response where low titers were represented in about half of the samples. Finally, pre- and post-vaccination samples were tested for neutralizing antibodies using the qualitative and semi-quantitative cPass sVNT protocols revealing undetectable or relatively low levels after the first vaccine dose and a decline in levels longitudinally over the months following the second dose. This wide range in neutralizing (blocking) antibodies from both natural infection and vaccination supports a differential immune response that may be attributed to several physiological and genetic factors underlining the potential for measuring SARS-CoV-2 neutralizing antibody titer levels post-vaccination to help ensure robust and prolonged immunity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article